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Background: CD4
+CD25
+ regulatory T-cells (Tregs) play a critical role in immune responses. We explored the status of Tregs in neo-
plastic and autoimmune hematologic diseases. We also evaluated the technical aspects of Treg measurement in terms of sample 
type and detection markers.
Methods: A total of 68 subjects were enrolled: 11 with AML, 8 with MDS, 10 with autoimmune diseases, and 39 controls. Tregs were 
analyzed in peripheral blood (PB) and bone marrow (BM) samples from each subject. Flow cytometry and the Human Regulatory T 
cell Staining Kit (eBioscience, USA) for CD4, CD25, and FoxP3 (forkhead box P3) were used.
Results: The CD4
+CD25
high/CD4 and CD4
+CD25
highFoxP3
+/CD4 populations were significantly correlated (P<0.0001). The AML and 
high-risk MDS groups had significantly larger CD4
+CD25
high/CD4 and CD4
+CD25
highFoxP3
+/CD4 populations in PB than the autoim-
mune (P=0.007 and 0.012, respectively) and control groups (P=0.004 and 0.006, respectively). Comparable findings were observed 
in BM. The CD4
+CD25
highFoxP3
+/CD4 population was significantly larger in PB than in BM (P=0.0003).
Conclusions: This study provides comparison data for Tregs in AML, MDS, and autoimmune hematologic diseases, and would be 
helpful for understanding the different immunologic bases of various hematologic diseases. Treg measurement using CD4, CD25, 
and/or FoxP3 in PB rather than in BM seems to be practical for routine hematologic purposes. Large-scale analysis of the diagnostic 
role of Treg measurement is needed.
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INTRODUCTION
The human immune system maintains the balance be-
tween protecting the host from pathologic microorganisms 
and avoiding excess immune reactions that could be harm-
ful to the host [1]. Aberrant immune reactions can cause 
serious damage to host, such as various autoimmune and 
inflammatory diseases. Naturally occurring thymus-derived 
CD4
+CD25
+ regulatory T-cells (Tregs) play a critical role in 
the control of immune responses in various clinical settings, 
including autoimmune diseases, allergic disorders, infec-
tions, transplantations, and cancers [2-5].
A number of previous studies reported a high percentage 
of Tregs in tumor tissues and peripheral blood (PB) from 
patients with various cancers, including lung cancer, breast 
cancer, hepatocellular carcinoma, gastric, and ovarian can-
cer [6-9]. They showed that a high percentage of Tregs or a 
low ratio of CD8
+ T-cells to Tregs was associated with poor 
prognosis and more advanced stage [7, 10, 11]. In addition 
to solid tumors, a few recent studies have demonstrated in-
creased Tregs in hematologic malignancies. The increase of 
Tregs was stage dependent and correlated with unfavorable 
cytogenetics [12-14]. However, some earlier studies were 
limited in that they used less specific detection markers for 
Tregs [13, 15, 16].
In spite of the many advanced diagnostic tools, differen-
tial diagnoses between clonal or neoplastic hematologic dis-
eases and non-clonal conditions are sometimes challenging. 
Since most non-clonal conditions such as aplastic anemia 
(AA) and primary immune thrombocytopenic purpura (ITP) 
are based on autoimmune processes, we can speculate that 
the proportion of Tregs might differ between neoplastic and 
autoimmune hematologic diseases. To the best of our knowl-232     www.kjlm.org
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edge, no previous study has directly compared Tregs betw-
een neoplastic and autoimmune hematologic diseases. In 
addition, most studies have shown the data for Tregs in PB, 
and the data on Tregs in bone marrow (BM) have been very 
sparse. BM Tregs have only been evaluated in neoplastic he-
matologic diseases.
In this study, we wanted to explore the status of Tregs and 
compare the proportion of Tregs between neoplastic and 
autoimmune hematologic diseases. Because we wanted to 
determine suitable conditions for Treg measurement in rou-
tine diagnostic practice, we also evaluated the technical as-
pects of Treg measurement, including sample types and the 
combination of detection markers. 
MATERIALS AND METHODS
1. Study population
A total of 68 subjects were enrolled in this study from June 
2009 until July 2010. There were 36 males and 32 females, 
and their median age was 57 yr (range, 18-85 yr). Twenty-
nine subjects were diagnosed with various hematologic dis-
eases: 11 patients with AML, 8 with MDS, 2 with AA, 5 with 
ITP, and 3 with autoimmune disease-related cytopenia such 
as systemic sclerosis or Sjogren’s syndrome. The 8 patients 
with MDS included 1 patient with refractory anemia with 
ring sideroblasts (RARS), 2 with refractory cytopenia and 
multilineage dysplasia (RCMD), and 5 with refractory ane-
mia and excess blasts (RAEB). The diagnoses were made by 
2 hematologists following the WHO classification [17]. The 
patients with MDS were divided into 2 groups (low-grade 
and high-grade MDS) because the role of immune responses 
in the pathogenesis of these 2 groups is known to be differ-
ent. Autoimmune processes have been suggested especially 
in low-grade MDS [18-20]. The low-grade MDS group in-
cluded low/intermediate-1 risk, and the high-grade MDS 
group included intermediate-2/high risk, based on the In-
ternational Prognostic Scoring System (IPSS) score. AA, ITP, 
and autoimmune disease-related cytopenia were categoriz  ed 
as the autoimmune group.
The control group (N=39) consisted of 11 patients with 
no evidence of specific hematologic diseases on BM exami-
nations and 28 healthy subjects who received regular check-
ups. The study groups did not differ in terms of age and sex 
(Table 1). This study was approved by the institutional ethics 
committee and informed consent was obtained from each 
enrolled subject.
2. Flow cytometry analysis for Tregs
PB and BM samples were obtained from all subjects, ex-
cept for 28 healthy subjects in the control group, from whom 
only PB samples were available. The samples were collected 
in sterile EDTA tubes during routine diagnostic or check-
up visits, and mononuclear cells (MNC) were separated by 
density gradient centrifugation using Ficoll (Ficoll-Paque; 
GE Healthcare Life Sciences, Milan, Italy). Isolated MNC 
layers were resuspended in phosphate buffered saline (PBS) 
at the concentration of 1×10
6 cells/mL.
For the analysis of Tregs, a Human Regulatory T Cell Stain-
Table 1. Characteristics and distribution of cell subpopulations in hematologic disease and control groups
AML group  
(N=11)
High-grade MDS group 
(N=5)
Low-grade MDS group 
(N=3)
Autoimmune group 
(N=10)
Control group* 
(N=39)
Age (yr) 53.0±17.8 58.9±22.8 38.7±15.8 55.5±20.7 45.1±9.6
Sex (male/female) 5/6 4/1 1/2 4/6 22/17
Peripheral blood
CD4
+ (%) 19.7±10.5 23.4±10.4 23.7±2.7 35.3±12.1 36.6±7.6
CD4
+CD25
high/CD4 (%)
† 8.0±3.7 8.2±4.1 4.0±0.8 4.5±1.6 4.6±1.5
CD4
+CD25
highFoxP3
+/CD4 (%)
‡ 7.0±3.5 7.5±3.9 3.6±0.9 3.9±1.8 4.0±1.3
Bone marrow
CD4
+ (%) 13.3±8.7 16.2±10.6 13.4±2.1 21.2±12.2 15.5±3.1
CD4
+CD25
high/CD4 (%)
§ 7.1±3.8 6.9±3.3 2.7±0.8 4.2±1.7 3.2±1.6
CD4
+CD25
highFoxP3
+/CD4 (%)
II 5.2±3.4 5.7±3.3 1.14±0.7 3.0±1.8 2.3±1.2
*In the control group, bone marrow analysis was done in 11 patients with no evidence of specific hematologic diseases on bone marrow examination; 
†AML vs autoimmune and 
control group: P=0.028 and 0.026, AML/high-grade MDS vs autoimmune and control group: P=0.007 and 0.004; 
‡AML vs autoimmune and control group: P=0.041 and 0.035, 
AML/high-grade MDS vs autoimmune and control group: P=0.012 and 0.006; 
§AML/high-grade MDS vs autoimmune and control group: P=0.015 and 0.003; 
IIAML/high-grade 
MDS vs autoimmune and control group: P=0.045 and 0.029. 
Data are expressed as mean±SD.
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ing Kit (eBioscience, San Diego, CA, USA), including fluo-
rescein isothiocyanate (FITC) CD4, phycoerythrin (PE) CD-
25, and phycoerythrin-cyanin 5 (PE-Cy5) FoxP3 (forkhead 
box P3) was used. Tregs were analyzed according to the ma-
nufacturer’s instructions. Isotype-negative controls included 
a mouse isotype matched non-relevant immunoglobulin to 
define the positive population. After gating the lymphocyte 
population, the CD4
+CD25
high population and the CD4
+CD 
25
highFoxP3
+ population were sequentially gated and analyz  ed. 
The percentage of FoxP3
+ cells (CD4
+CD25
highFoxP3
+) was 
counted in the CD4
+ population (Fig. 1). Multicolor flow 
cytometry analysis was performed using Cytomics FC500 
and CXP software (Beckman Coulter, Fullerton, CA, USA).
3. Statistical analysis
Chi-square test or Fisher’s exact test was used for categor-
ical variables and Student’s t-test or Kruskal-Wallis test was 
used for continuous variables, as appropriate. Pearson’s cor-
relation was used for comparisons. The statistical analysis 
was performed using SPSS Software (version 14.0; SPSS Inc., 
Chicago, IL, USA) and MedCalc Statistical Software (ver-
sion 11.2.1; Mariakerke, Belgium). P values of ≤0.05 were 
considered statistically significant. 
RESULTS
1. PB Tregs in each group 
In general, the populations of CD4
+CD25
high/CD4 and 
CD4
+CD25
highFoxP3
+/CD4 cells were significantly correlated 
(Y=0.9326X-0.2901, R=0.9674, P<0.0001). The CD4
+CD 
25
high/CD4 population (5.56±2.82%) was slightly larger than 
the CD4
+CD25
highFoxP3
+/CD4 population (4.90±2.67%) 
with a mean difference of 0.66% [CD4
+CD25
high-CD4
+CD 
25
high FoxP3
+] (Fig. 2). 
The populations of CD4
+CD25
high/CD4 and CD4
+CD 
25
highFoxP3
+/CD4 cells in the AML group were significantly 
larger than those in the autoimmune (P=0.028 and 0.041, 
respectively) and control groups (P=0.026 and 0.035, re-
spectively). The high-grade MDS group also had larger pop-
ulations of CD4
+CD25
high/CD4 (8.2±4.1%) and CD4
+CD 
25
highFoxP3
+/CD4 (7.5±3.9%) cells than the low-grade MDS 
(4.0±0.8%; 3.6±0.9%), autoimmune (4.5±1.6%; 3.9±1.8%), 
and control groups (4.6±1.5%; 4.0±1.3%); however, the dif-
ference was not statistically significant (Table 1, Fig. 3). When 
the AML and high-grade MDS groups were analyzed toge-
ther as a single category, they had significantly larger popu-
lations of CD4
+CD25
high/CD4 and CD4
+CD25
highFoxP3
+/
CD4 cells than the autoimmune group (P=0.007 and 0.012, 
respectively) and the control group (P=0.004 and 0.006, re-
spectively, Fig. 3). There were no differences in the Treg po-
pulations among the low-grade MDS, autoimmune, and con-
trol groups. 
2. BM Tregs in each group
The populations of CD4
+CD25
high/CD4 and CD4
+CD 
25
highFoxP3
+/CD4 cells were also significantly larger in the 
AML and high-grade MDS groups than in the autoimmune 
group (P=0.015 and 0.045, respectively) and the control 
group (P=0.003 and 0.029, respectively, Table 1, Fig. 4). In 
spite of the small number of patients, the high-grade MDS 
group had significantly larger populations of CD4
+CD25
high/ 
CD4 and CD4
+CD25
highFoxP3
+/CD4 cells than the low-grade 
MDS group (P=0.044 and 0.034, respectively; Table 1, Fig. 
4). There were no statistically significant differences in the 
Fig. 1. Analysis of Tregs using flow cytometry. Mononuclear cells were stained with CD4-FITC, CD25-PE, and FoxP3-PE-Cy5 antibodies. After gating the lympho-
cyte population, the CD4
+CD25
high population and the CD4
+CD25
highFoxP3
+ population were sequentially gated and analyzed. The percentage of FoxP3
+ cells (CD4
+ 
CD25
highFoxP3
+) within the CD4
+ population was calculated. In the case shown above, the proportion of CD4
+CD25
high cells is 2.8% of CD4
+ population and 92.8% 
of that population is Foxp3 positive (2.59% of CD4
+ population), defined by isotype control. 
Abbreviations: SSC, side scatter; FSC, forward scatter; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PE-Cy5, phycoerythrin-cyanin 5; FoxP3, forkhead box P3.
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Treg populations among the low-grade MDS, autoimmune, 
and control groups. 
3. Comparison of Tregs in PB and BM 
The populations of Tregs (CD4
+CD25
highFoxp3
+/CD4) in PB 
and BM were significantly correlated (Y=0.9560X+ 1.5534, 
R=0.8440, P<0.0001). However, the Treg population was 
significantly larger in PB than in BM (mean difference, 1.37± 
1.83%; P=0.0003) (Fig. 5). 
Fig. 2. Correlation and difference between the CD4
+CD25
high/CD4 and CD4
+CD25
highFoxP3
+/CD4 populations in peripheral blood. (A) The 2 populations were sig-
nificantly correlated (Y=0.9326X - 0.2901, R=0.9674, P<0.0001). (B) The CD4
+CD25
high/CD4 population (5.56±2.82%) was slightly larger than the CD4
+CD 
25
highFoxP3
+/CD4 population (4.90±2.67%) with mean difference of 0.66%.
Abbreviation: FoxP3, forkhead box P3.
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Fig. 3. Peripheral blood CD4
+CD25
high/CD4 (A) and CD4
+CD25
highFoxP3
+/CD4 populations (B) in each group. Both PB CD4
+CD25
high/CD4 and PB CD4
+CD25
highFoxp3
+/ 
CD4 populations were significantly larger in the AML and high-grade MDS groups compared with the autoimmune and control groups, by Student’s t-test. Shown 
are the mean (middle bar) and 2SD (error bar) for each group. 
Abbreviations: PB, peripheral blood; FoxP3, forkhead box P3; MDS-H, high-grade MDS; MDS-L, low-grade MDS; AI, autoimmune group. Moon H-W, et al.  •  Tregs in Hematologic Diseases
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DISCUSSION
Tregs, a small subpopulation (5-10%) of CD4
+ T-cells, 
were first described by Sakaguchi et al. [4]. Accumulating 
evidence shows that Tregs maintain immunologic tolerance 
by suppressing the activation and expansion of self-reactive 
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Fig. 4. Bone marrow (BM) CD4
+CD25
high/CD4 and CD4
+CD25
highFoxP3
+/CD4 populations in each group. (A) The BM CD4
+CD25
high/CD4 population was significantly 
larger in the AML and high-grade MDS groups than in the autoimmune and control groups. (B) The BM CD4
+CD25
highFoxP3
+/CD4 population was significantly 
larger in the AML and high-grade MDS groups than in the autoimmune and control groups. The low-grade MDS group had significantly smaller populations of 
CD4
+CD25
high/CD4 and CD4
+CD25
highFoxP3
+/CD4 cells compared with the high-grade MDS group. Shown are the mean (middle bar) and 2SD (error bar) for each 
group. 
Abbreviations: BM, bone marrow; FoxP3, forkhead box P3; MDS-H, high-grade MDS; MDS-L, low-grade MDS; AI, autoimmune group. 
Fig. 5. Comparison of Tregs (CD4
+CD25
highFoxP3
+/CD4) in peripheral blood (Y axis) and bone marrow (X axis). (A) The 2 populations were significantly correlated 
(Y=0.9560X+1.5534, R=0.8440, P<0.0001). (B) The percentage of PB Tregs (5.52±3.41%) was significantly higher than that of BM Tregs (4.16±3.00%) 
(mean difference 1.37±1.83%, P=0.0003 by paired t-test).
Abbreviations: PB, peripheral blood; BM, bone marrow; Treg, regulatory T-cells. 
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immune cells, including CD4
+CD25
- T-cells, CD8
+ T-cells, 
dendritic cells, natural killer cells, and B-cells, by cell-to-cell 
contact in a dose-dependent manner [1, 21, 22]. In addition 
to naturally-occurring Tregs, several subsets of Tregs, inclu-
ding antigen-induced Tregs (e.g., Tr1 and Th3 cells), and 
adaptively induced CD4
+ Tregs in the periphery by conver-
sion of CD4
+CD25
- T-cells and CD8
+ T-cells, have been re-
cently identified [6, 22]. 
In this study, we evaluated the proportion of CD4
+CD25
+   
FoxP3
+ Tregs in PB and BM samples from patients with var-
ious hematologic diseases. To the best of our knowledge, no 
previous study has directly compared the PB and BM Treg 
populations among clonal and autoimmune hematologic 
diseases. Moreover, there has been very little data on the dis-
tribution of Tregs in normal healthy Asian populations.
According to our data, the percentage of CD4
+CD25
high 
FoxP3
+ Tregs in the control group was 4.0±1.3% in PB and 
2.3±1.2% in BM. Treg data in control individuals varied 
widely across studies, ranging from 0.5% to 12% in PB; and 
the percentage of Tregs in BM was consistently lower than 
in PB [15, 23-26]. Such wide variation may be due to differ-
ences in detection markers, gating strategies, and parame-
ters. Although most studies analyzed the percentage of Tregs 
within the CD4
+ cell population using CD4, CD25, and Fox-
P3, some studies used only CD4 and CD25 or other param-
eters such as absolute counts and percentages in total lym-
phocytes [12, 24]. In almost all these studies, the number of 
control subjects was very limited. Moreover, very heteroge-
neous groups of patients were used as controls, and most of 
them could not be considered as true healthy, reference in-
dividuals. Therefore, both assay standardization and deter-
mination of the reference range in each ethnic population 
using large numbers of healthy individuals are needed for 
the routine clinical use of Tregs.
In our study, the AML and high-grade MDS groups had 
significantly increased Treg populations in both PB and BM 
compared with the control and autoimmune groups. Re-
cently, an increased proportion of Tregs in PB was reported 
in hematologic malignancies such as AML, multiple my-
eloma, chronic lymphocytic leukemia, lymphoma, and high-
grade MDS [22, 25]. In clonal hematologic diseases, increased 
Tregs in BM was also significant, which was in agreement 
with previous studies [16, 18]. Although the results for Tregs 
in BM and PB were well correlated, the proportion of Tregs 
was lower in BM, and the difference in BM between groups 
was less significant.
Regarding autoimmune hematologic diseases such as AA 
and ITP, a few recent studies reported reduced proportion 
and function of Tregs in PB [24, 26, 27]. In addition, there 
is evidence for an association between early-stage MDS and 
autoimmune manifestations, which has not been shown for 
high-grade MDS [19]. A recent study reported a lower pro-
portion of PB Tregs in early MDS [18]. In our study, the low-
grade MDS group also had a low proportion of Tregs in both 
PB and BM, which was comparable to those of the autoim-
mune and control groups. 
Tregs are identified by the expression of CD25, which is a 
component of the high affinity interleukin 2 receptor, and is 
functionally essential for Treg development. However, CD25 
is known to be not specific for Tregs, since it is also expressed 
by effector T-cells. To date, expression of FoxP3, a member 
of the forkhead/winged-helix family of transcriptional fac-
tors, is considered an optimal marker for Tregs [1, 28]. Nev-
ertheless, our data showed that CD4
+CD25
high/CD4 and CD 
4
+CD25
highFoxP3
+/CD4 cell populations were significantly 
correlated (P<0.0001). In addition, the PB CD4
+CD25
high/
CD4 and PB CD4
+CD25
highFoxP3
+/CD4 populations were 
significantly different between the groups with neoplastic 
disease and the autoimmune and control groups (Fig. 3). 
Regarding sample type, the Tregs in PB differed more sig-
nificantly between groups than those in BM. Previous stud-
ies showed that increased Tregs in cancer is a generalized 
phenomenon, both in the tumor microenvironment and in 
PB [22]. From a technical point of view, BM processing is 
more difficult due to fat tissues and lower lymphocyte pro-
portions; thus, sampling from PB would be better than sam-
pling from BM for Treg measurement in routine clinical set-
tings. However, the clinical significance of Tregs in PB and/
or BM needs to be further evaluated using large clinical data 
sets. 
In conclusion, this study directly compared Tregs in vari-
ous hematologic diseases, including AML, MDS, and auto-
immune hematologic diseases. In spite of the limited study 
population, our data would be useful in understanding the 
different immunologic bases of various hematologic diseases. 
Measurement of Tregs using CD4, CD25, and/or FoxP3 in 
PB rather than BM seems to be practical for routine hema-
tologic purposes. The diagnostic role of Treg measurement 
needs to be further evaluated with a larger clinical data set.
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